Table 3 Prognostic factors of lacrimal gland tumor (multivariate analysis)
Factors | Disease specific survival | Local control | Distance metastasis control | Progression-free survival | |||||
|---|---|---|---|---|---|---|---|---|---|
N | p | OR | p | OR | p | OR | p | OR | |
Age | |||||||||
≤35 | 17 | Reference | Reference | Reference | Reference | ||||
>35 | 19 | 0.291 | 297.65 | 0.902 | 0.884 | 0.539 | 3.687 | 0.26 | 2.58 |
Gender | |||||||||
Male | 20 | Reference | Reference | Reference | Reference | ||||
Female | 16 | 0.35 | 126.92 | 0.915 | 0.899 | 0.106 | 117.23 | 0.881 | 1.15 |
Tumor histology | |||||||||
Adenoid cystic carcinoma | 26 | Reference | Reference | Reference | Reference | ||||
Adenocarcinoma | 7 | 0.165 | 157.03 | 0.82 | 0.712 | 0.103 | 81.63 | 0.633 | 1.652 |
Myoepithelial carcinoma | 3 | 0.855 | 0.282 | 0.979 | 0 | 0.976 | 0 | 0.985 | 0 |
T category | |||||||||
T1-2 | 29 | Reference | Reference | Reference | Reference | ||||
T3-4 | 7 | 0.955 | 0.001 | 0.949 | 0 | 0.922 | 0 | 0.19 | 0.041 |
Tumor status | |||||||||
Primary | 30 | Reference | Reference | Reference | Reference | ||||
Recurrence | 6 | 0.893 | 0.311 | 0.193 | 30.183 | 0.953 | 158.1 | 0.317 | 7.044 |
Margin status | |||||||||
R0 + R1/close margin | 13 | Reference | Reference | Reference | Reference | ||||
R2/biopsy | 23 | 0.974 | 0.875 | 0.968 | 0.957 | 0.776 | 1.804 | 0.426 | 0.506 |
Median Tumor diameter | |||||||||
<4 cm | 18 | Reference | Reference | Reference | Reference | ||||
≥ 4 cm | 18 | 0.168 | 51.98 | 0.944 | 111.38 | 0.909 | 157.66 | 0.016 | 120.55 |
Bone involvement* | |||||||||
No | 18 | Reference | Reference | Reference | Reference | ||||
Yes | 16 | 0.555 | 3.515 | 0.025 | 8.465 | 0.909 | 147.76 | 0.003 | 20.485 |
Extension beyond orbit | |||||||||
No | 29 | Reference | Reference | Reference | Reference | ||||
Yes | 7 | 0.914 | 832.06 | 0.582 | 0.238 | 0.095 | 55.26 | 0.809 | 1.654 |